Allergologia et immunopathologia

www.elsevier.es/ai

REVIEW

Skin prick tests and allergy diagnosis

João Antunes*, Luís Borrego, Ana Romeira and Paula Pinto

Serviço de Imunoalergologia, Hospital Dona Estefânia, Lisbon, Portugal

KEY WORDS

Skin;
Prick test;
Epicutaneous;
Diagnosis;
Allergen extract;
Technique.

Abstract

Skin testing remains an essential diagnostic tool in modern allergy practice. A significant variability has been reported regarding technical procedures, interpretation of results and documentation. This review has the aim of consolidating methodological recommendations through a critical analysis on past and recent data. This will allow a better understanding on skin prick test (SPT) history; technique; (contra-) indications; interpretation of results; diagnostic pitfalls; adverse reactions; and variability factors.

© 2008 SEICAP. Published by Elsevier España, S.L. All rights reserved.

Skin has an important physiological role in the internal balance homeostasis and constitutes a crucial barrier against external aggressions, with well-known immunological properties.¹ It has been used by allergists for decades as an easily assessed laboratory of the immunological status of the individual.

The first skin testing technique was developed by Charles H. Blackley in 1865, a Manchester homeopathic physician with allergic rhinitis. He abraded a quarter-inch area of his skin with a lancet and then applied grass pollen grains.² The so-called scratch test was later adopted by Schloss for the diagnosis of food allergy in children.³ Epicutaneous tests can be divided into scratch tests and prick/puncture tests. The first method, proposed by Blackley², implied a linear scratch without drawing blood and could either be performed first, with the extract then dropped on the abraded skin, or be made through a drop of extract.⁴ Although it was used extensively in the past, this technique became progressively obsolete due to patient discomfort, poor reproducibility, possible residual lesions and newer and innocuous proce-

dures.⁴ Therefore, scratch test is mentioned here for historical purposes only. It was Sir Thomas Lewis who, in 1924, first applied skin prick tests (SPT).⁵ Nevertheless, their generalised use in clinical practice only became a reality about 30 years ago, as a result of technique modifications proposed by Pepys.⁶ For the purpose of this review and for easier comprehension, skin testing will be referred interchangeably as SPT, whatever device is used for its application.

In 1966, Ishizaka's work on immunoglobulin E (IgE) and immediate hypersensitivity reactions⁷ established the scientific *corpus* to what was done till then on a strictly empiric basis.

As written by Dr Walzer in 1974, "the fact that skin testing has not turned out to be a simple and completely reliable technique does not detract from the fact that, when it is intelligently and skilfully performed, it remains the most effective diagnostic procedure in reaginic allergic disorders".⁸

The reliability of skin testing and proper documentation of test results are essential in allergy practice. A recent survey to all physician members and fellows of the American College of Allergy, Asthma and Immunology practicing in the

*Corresponding author.

E-mail: jdiasantunes@hotmail.com (João Antunes)

United States detected a significant degree of variability regarding skin test devices, extract concentrations, interpretation and documentation of results and quality assurance procedures.⁹

This heterogeneity observed in clinical practice justifies the interest and relevance of the present review work. It is our aim to consolidate important technical recommendations, providing a new insight on the subject.

Skin prick tests

General considerations and indications

It is imperative that the clinician be fully aware of the clinical indications, correct technique, and interpretation criteria, as well as the risks and limitations of SPT. Skin testing should always be an adjunct to history and physical examination and not a substitute for medical evaluation.

SPT confirm the diagnosis of immediate hypersensitivity reactions.^{4,10}

On skin level, the IgE-mediated immune response is dependent on both chemical and neurogenic mediators.^{11,12} After intracutaneous injection, allergens cross-link preformed IgE bound to the high-affinity receptor FcεRI mast cells and a complex signal transduction cascade is activated. This eventually culminates in mast-cell degranulation beginning in seconds, with release of a variety of preformed inflammatory mediators. Among these are histamine – a short-lived vasoactive amine that causes an immediate increase in local blood flow and vessel permeability – and enzymes such as mast-cell chymase, tryptase and serine esterases.¹¹ A wheal and flare reaction develops within minutes after superficial injection of antigen into the epidermis and lasts for up to 30 minutes. On activation, mast cells also synthesise and release chemokines, lipid mediators such as prostaglandins, leukotrienes and platelet-activating-factor, and additional cytokines such as interleukins 4 and 13 which perpetuate the Th2 response.¹¹ These changes can sometimes be followed by a late-phase reaction (LPR), which is extremely rare and almost exclusive to patients sensitised to moulds, grass and parietaria pollens.¹³

In a positive reaction, histamine can be detected only at the centre of the wheal, not in the periphery. It is suggested therefore that after allergen challenge, the mediators released by the challenged mast cell induce an axon reflex by direct stimulation of c-fibres. This induces the release of neurogenic peptides and mast cell mediators from “the next” mast cell, becoming the major players in the immediate wheal and flare reaction.¹²

Skin testing can be used to select evicution measures and/or specific immunotherapy.¹⁴

To optimally define test performance, a method should be reproducible and validated by comparison with gold standard methods. Direct challenge tests under supervision of a physician are appropriate ways to confirm or refute the validity of SPT. It provides objective evidence for sensitivity, specificity, predictive values and likelihood ratios. When compared to gold standard procedures, i.e. organ challenges such as nasal bronchoprovocation challenge or oral provocation challenge, SPT have demonstrated good results.¹⁵⁻¹⁸ The simplicity, rapidity of performance, low cost and high sensi-

tivity make skin testing preferable to in vitro testing for determining the presence of specific IgE antibodies (sIgE). It is important to note the higher sensitivity of SPT when compared to sIgE dosing. Nevertheless, every positive result must be correlated with history and physical findings since a positive skin reaction does not necessarily imply the diagnosis of allergy.¹⁹

Interpretation of skin tests is highly dependent on the constitutive allergenicity, potency and stability of the allergen extract. For this reason, SPT sensitivity tends to be higher among aeroallergens, in particular pollens, house dust mite, fungi and certain epidermals.¹⁰

In clinical practice, skin testing has been extensively used for assessing sensitisation to inhalant allergens. SPT is useful to confirm or exclude a suspected diagnosis of allergic rhinitis, allergic conjunctivitis or asthma triggered by allergens^{10,20,21} and to demonstrate sensitisation to inhalant occupational allergens.^{22,23}

Previous observations suggest that skin test positivity at an early age is associated with subsequent development of rhinitis and wheeze.²⁴⁻²⁶ The role of allergic sensitisation as a cause of eczema is less clear.²⁷

Skin testing in food allergy is common practice as well, although less reliable for commercial extracts of fruits and vegetables, as explained below.²⁸ The clinical utility of SPT in patients with food allergy suspicion, especially infants and children, has been evaluated in various studies using oral food challenges and sIgE.

Most previous studies on food allergy obtained a concordance rate between SPT with commercial extracts and oral challenges from 60% to 85%²⁸⁻³², specificity being generally lower, in the range of 40% to 80%.²⁸ A negative result is useful to exclude type I reactions to food allergens (negative predictive accuracy > 95%)³² but a positive result may or may not be associated with true clinical reactions. The overall concordance between a positive SPT and positive oral challenge differs between authors, but consensus exists regarding clear superiority of fresh food when compared to commercial extracts, as shown by Ortolani et al.³³, Rosen et al.³⁰, and Norgaard et al.³⁴ With fresh food, sensitivity usually exceeds 90% and can even reach 100%.³⁴ This is particularly important when a strong suspicion of food allergy subsists after negative results with commercial extracts. Fresh food testing makes use of a different procedure, the prick-prick technique.

Under carefully defined circumstances, SPT can also be used as a primary approach to drug and hymenoptera venom. In such cases however, intradermal tests are usually required for a correct diagnosis. For most chemicals associated with occupational allergy it is not indicated, with the exception of agents known to be implicated in IgE reactions, such as platinum salts, acid anhydrides, polyisocyanates, sulphonechloramide and succinylcholine analogues.³⁵⁻³⁷

Technique

The goal for the allergist is to perform skin testing with devices which minimise both false positive and false negative results while reducing patient discomfort. SPT should be a non-traumatic procedure (blood-free) and several sharp instruments such as a hypodermic needle, solid bore needle,

lancet with or without bifurcated tip, and multiple-head devices, may be used.³⁸

Historically, in the method first introduced by Pepys, the needle or blood lancet tip was inserted at an angle of 60.° to 70.° to the skin surface, gently lifting the superficial epidermal layers to create a small break in the skin.⁶

In 1979 a new method – puncture test – was proposed by Østerballe & Weeke, using a lancet with 1 mm tip and shoulders to prevent further penetration.³⁹ Lancets should be pressed with equal strength at 90° to the skin surface through a drop of extract or control solutions.⁴ This technique appears to be more precise than the original SPT method proposed by Pepys.^{40,41}

Multiheaded devices are designed to first be dipped into the extract bottles, then applied to the skin in one step. They appear to be more painful than single devices but it is noteworthy that with a minimal increase in pain, as many as eight times more tests are applied, rendering multiheaded devices particularly useful in paediatric ages.³⁸

Lancets should be sterilised, a fresh lancet for each prick, with normalised measures and each lancet should be used only once for each extract, in order to avoid unintentional pricks, blood borne infections and allergen contamination. Metal lancets with 1mm penetration limit are considered equally efficient and less painful than other synthetic devices with 1.4 or 1.6 mm penetration limits.³⁹ The penetration limit is therefore a determinant factor when considering test efficacy and patient comfort, rendering metal lancets preferable when compared to other synthetic devices.¹³ Nevertheless, an objective comparison has not shown a clear-cut advantage for any single or multitest device and optimal results can be obtained by choosing a single prick/puncture device, and properly training its use.^{38,40,42}

Antiseptic solutions are recommended before SPT and skin should be totally dry before procedure.⁴³

Recommendations have been made regarding the appropriate placement of allergen extracts. The recommended distance for skin prick testing has varied between 2 and 5 cm⁴⁴ and test sites should be marked with an appropriate code.⁴ It is possible, however, for a positive reaction to enhance false-positive skin reactions at an adjacent site, even over the range of 5 cm.⁴³⁻⁴⁵

SPT are usually performed on the volar surface of the forearm, at least 5 cm above the wrist and 3 cm below antecubital fossae,⁴ the least and most reactive areas of the upper limb, respectively. The tests can also be done on the upper arm or the back, with special attention to avoid reactivity differences between locations.⁴³ It should be taken into account that not only is the back 20% more reactive than the forearm but specific locations on the back vary in reactivity as well.^{46,47} Therefore, a minimum of 2 cm distance between each SPT should be adopted.

For an accurate interpretation of wheal and flare reactions to allergens, both positive and negative tests should be used. A negative control solution is required to evaluate unspecific reactions related to prick testing trauma (dermographism).^{4,48,49} A saline solution, phenol at 0.5% or glycerine at 50% are recommended.¹⁰

For positive control, histamine dihydrochloride 10 mg/ml (54.3 mmol/l), equivalent to 6.14 mg/ml of histamine base, or codeine phosphate at 9% can be recommended.⁴⁹ Some authors advocate the use of histamine at 1 mg/ml⁵⁰; how-

ever, in a study by Morais de Almeida et al., the concentration of 1 mg/ml consistently presented negative results in more than 10% of the patients.¹³ Therefore, histamine at 1 mg/ml should be definitely abandoned.

The prick-prick test requires a different procedure, pricking the food first, and then the skin, using the same needle; or pricking the skin through food in a single manoeuvre.⁵¹ Foods with a hard consistency, such as peanut, can be ground, diluted in buffered saline at 1/3 weight/volume (w/v), or 500 mg of food to 1.5 ml of saline.⁵²

Dreborg recommends at least two parallel tests performed with the same material in every patient with the exception of infants, in order to assure precision, as single negative tests (5%) will be obtained in sensitised patients even with skilled technicians.⁴ In duplicate tests, the diameter should not vary more than 1 mm.⁵³⁻⁵⁶ Several publications have provided innovative methods to assure skin test validity. A suggested protocol for quality assurance testing and proficiency testing for SPT can be found in literature.¹⁰ In Europe, a coefficient variation of less than 20% after histamine control test has been suggested⁵⁷, whereas a recent Childhood Asthma Management Study considered a variation inferior to 30%.⁵⁸

Reading and interpretation

The size of the papule is of paramount importance in SPT. However, both erythema and wheal should be measured for proper interpretation.¹⁰

Østerballe and Weeke³⁹ demonstrated that the wheal size with histamine peaks earlier (9-12 min) than with allergens (13-16 min). In a recent study, using laser Doppler flow imaging and scanning of drawn wheal sizes, the maximum histamine wheal size was reached at 20 minutes.⁵⁹ We therefore propose a consensus reading time for both positive control and allergen reactions at 20 minutes post-prick.

A valuable option concerning appropriate documentation of skin test results consists in outlining the wheal and flare reaction with a felt-tip pen and transferring results with transparent tape to a blank sheet of paper.^{4,13}

Various indices have been used for interpretation of skin reactions. The papule's area is the most accurate^{49,59} and can be evaluated by planimetry, either directly with image-processing programs or from a traced copy.^{13,60} The interpretation of the skin prick test is subject to inter-observer variation. To overcome this issue, computerised procedures have been proposed, allowing a more precise area evaluation.^{60,61} Other methods such as laser Doppler technique⁶² and ultrasound⁶³ have been tested with success.

The size of the reaction can also be assessed using:

- minimal diameter;
- mean wheal diameter, calculated as the sum of the largest diameter and its largest orthogonal diameter divided by 2; or
- skin index, defined as the ratio of allergen wheal diameter divided by the histamine wheal size.

The SPT result should be considered positive if:

- minimal wheal diameter is greater than 3 mm or;
- mean diameter is 3 mm or larger; and/or
- skin index superior to 0.6.

Of the criteria explained above, mean wheal diameter is the most commonly used.

The skin reaction is considered positive if the wheal's area is 7 mm² or higher, which corresponds approximately to a mean diameter of 3 mm.^{9,40,57,64,65}

The degree of erythema (flare) is considered to be a non-specific reaction of the skin to the trauma of the puncture.⁶⁶ Nevertheless, some authors consider a positive reaction if the mean flare diameter is over 10 mm.⁴⁹

The results obtained can only be correctly assessed and taken into account with valid positive and negative control reactions. Thus, histamine's papule mean diameter should be greater than 3 mm and negative control should not exceed 3 mm with erythema diameter inferior to 10 mm. Devices that systematically produce negative control wheals over 3 mm should be avoided.⁶⁷ Stuckey et al. found that patients with more positive sensitisations and higher total IgE have larger histamine papules.⁶⁸

Qualitative scoring (0 to 4+; 0 or +) is no longer recommended because of marked variability between observers.^{69,70}

Wheal size has assumed greater diagnostic significance due to the positive correlation with clinical symptoms severity.⁷¹⁻⁷⁴ Investigating graduated test responses and establishing probability decision points might improve diagnostic accuracy and predict positive reactions during organ challenge.⁷⁵ In a previous study, especially regarding food allergy, Sporik⁷⁴ defined specific wheal diameters as '100% diagnostic'. In his work, cut-off values were proposed for cow's milk (≥ 8 mm), hen's egg (≥ 7 mm) and peanut (≥ 8 mm), suggesting that children exceeding these limits are allergic to this specific food. These recent advances might obviate the need for oral challenge in the future.⁷⁴⁻⁷⁶ These cut-off points vary for different allergens, being more accurate for cow's milk and hen's egg than for soy or wheat. Additionally, different populations may exhibit significant variability. Even though there is a correlation between SPT result or sIgE and likelihood of a clinical reaction, sensitisation level does not always correlate with allergic manifestations.⁷⁷⁻⁷⁹

One study points to between 7.5% and 19% asymptomatic sensitisations among Finnish schoolchildren.⁸⁰ Skin test reactivity to inhalant allergens is reduced in asymptomatic sensitisations when compared with symptomatic patients.⁸¹ Asymptomatic sensitisation is generally considered a pre-morbid state of allergic disease, and has been proven to be a risk factor for the development of allergic rhinitis in children and young adults.^{82,83} Bødtger et al., in a 3-years follow-up study, showed that adults with asymptomatic skin sensitisation to birch pollen have an increased risk (about 60%) of developing hay fever.⁸²

Several studies have demonstrated that positive SPT in infancy, especially to hen's egg, predicts subsequent presence of eczema in childhood.⁸³⁻⁸⁶ Thus, sensitisation in asymptomatic children can precede and predict the development of eczema.⁸⁷

Limitations

In the past, the manufacture of skin test solutions imposed important technical limitations. The recent availability of standardised commercial extracts constitutes a major achievement in allergy testing. Allergen extracts are com-

plex mixtures derived from natural source materials and as such are prone to natural variation, requiring proper standardisation to ensure consistency and reproducibility. Some physicians report non-negligible variability between extracts from different manufacturers, easily attested in our daily practice.^{88,89} Quality of allergen extracts is dependent on several parameters such as raw material quality, proper test extractions, adequate processing and removal of low molecular weight components by dialysis or filtration.⁹⁰ Stability, potency and allergen concentration are also determining.

The most internationally recognised way to express allergen extract strength is micrograms of major allergen because this appears to correlate well with overall biological potency of the extract.⁹¹ In-house references should be characterized with respect to dry weight, allergen complexity, major allergen content and IgE binding capacity. Biological activity should ideally be assessed *in vivo*, with skin testing.⁹⁰⁻⁹² However, the methods used differ from manufacturer to manufacturer, making products from different companies impossible to compare.⁹³

Non-related allergen mixtures may account for loss of biological potency as a consequence of excessive dilution or enzymatic deterioration of the epitopes. Time and higher temperatures can also accelerate the decay process. To assure stability, allergens are usually preserved with 50% glycerine and stored under cold (4°C).^{94,95}

Recombinant allergens offer future interesting perspectives as *in vivo* diagnostic tools. These genetically engineered molecules appear to be highly specific, safe and biologically active. Their sensitivity, however, appears to be lower when compared to natural allergen extracts.^{89,96}

Which allergens to test is a common doubt in daily practice. A recent survey performed in the United States showed that most allergists do not rely on history when choosing which allergens to use to perform skin testing.⁹

When considering inhalant allergy, several criteria should be thought-out before choosing skin testing reagents, such as botanical and aerobiological surveys. Flowering season, types and levels of pollens and spores along the year and peak days of pollination should be considered. Annual pollen sampling data in various countries are now available on-line.^{97,98} Air composition and concurrent allergy symptoms during recurrent seasons constitute the best indicators in the selection of appropriate outdoor aeroallergens for skin testing.¹⁰

The influence of pollen load is more evident in sIgE changes than on SPT reactions or clinical symptoms.⁹⁹

Regarding food allergy, SPT can be performed both with commercial allergen extracts and fresh foods. Fresh food is often used as it more accurately reflects the patient's life. In a French study it was demonstrated that fresh foods were more reliable in food allergy diagnosis than commercial extracts.¹⁰⁰ Commercial extracts of fruits and vegetables (e.g., apples, oranges, bananas, potatoes, carrots, and celery), are likely to lose biological properties with time, reinforcing the role of prick-prick method with fresh food.¹⁰⁰ This technique is also valuable when there are differences in the allergenicity of different cultivar strains (e.g., apples) or when no commercial extracts are available.¹⁰¹

Although prick-to-prick tests are widely used, it is important to notice that they are not standardised, often give

false-positive results, and still bear the risk of systemic reactions, as discussed in later sections.

Instead of fresh food, freezing aliquots may facilitate skin prick testing in particular cases. Freezing cow's milk and hen's egg at -20°C has been tested and it does not alter the allergenic properties of each component.¹⁰² However, these results cannot be transferred automatically to other foods without further testing.

Furthermore, commercial extracts may produce false-negative results since storage, cooking or digestive process may induce immunological alterations in relevant allergens, rendering a particular food more allergenic than achieved by commercial extracts.¹⁰

The presence of active cutaneous lesions, as commonly observed in patients with active atopic dermatitis, impair the proper SPT reading, and constitute a contra-indication to skin test procedures.^{4,48,103} Nevertheless, SPT can be performed in eczematous infants since no lesions exist on testing area. This can be useful as infants with eczema in the first 2 years of life with concomitant allergic sensitisation have a greater risk of childhood asthma and allergic rhinitis than infants with non-atopic eczema.¹⁰⁴

Patients with dermographism should be excluded as it is difficult to distinguish between a true or false positive result, invalidating any conclusions.⁴

In such circumstances involving extensive skin disease; or in patients under skin test suppressive therapy (for example, antihistamines) that cannot be discontinued; uncooperative patients; or when the history suggests an unusually high risk of anaphylaxis from skin testing, sIgE immunoassays may be preferable to skin testing.

False-positive reactions can be due to skin trauma, mostly in patients with dermographism⁴, as explained above, but also to contaminated allergen extracts (occurring during extract preparation or simply for not changing lancets during SPT)¹⁰⁵ or cross-reactivity phenomena.¹⁰⁶ Cross-reactivity depends on the type of allergens involved, in particular their structural and sequential similarity.¹⁰⁶ Pan-allergens responsible for cross-reactivity in vegetables are pathogen-related proteins (PRP) and profilins.¹⁰⁷ For invertebrates, tropomyosin is the most implicated protein. For vertebrates, several allergens are implicated: parvalbumin (fish), livetin and ovotransferrin (egg and birds) and casein (milk).¹⁰⁸

Extensive cross-reactivity has been described among aeroallergen-sensitised patients.^{10,109} House dust mites, epidermals, but most of all, pollens have been widely studied. Therefore, testing with multiple locally prevalent pollens may be required to avoid significant omissions. Cross-allergenicity among major classes of airborne fungi has not been well delineated so far.¹⁰

With regard to food allergy, we shall briefly mention the most interesting and relevant syndromes as it can be useful to better understand skin test results. Patients with: 1) birch apple; 2) artemisia-celery-carrot-spices; 3) grass-peach; 4) plantago-melon; 5) latex-fruits; 6) dust mites-seafood; 7) bird-egg; 8) pig-cat; 9) shellfish; 10) peanut, soybean and other legumes; 11) tree nuts; 12) *rosaceous* fruits; and 13) cereal grains can be expected to show cross-reactivity with SPT.

Concerning false-negative results, special attention should be given to patient's age, concomitant drugs and diseases such as HIV infection or chronic renal insufficiency, which

may inhibit skin reactivity.¹⁰ Even when all quality parameters are considered, patients with evident allergic symptoms can still have negative SPT. It is important to consider that non-IgE mechanisms, impossible to be assessed by SPT, can be implicated in patient's complaints. Powe et al.¹¹⁰ demonstrated that inflammation in non-allergic rhinitis may be a consequence of localised IgE-mediated reactions, not involving systemic Th2 responses or atopy. Therefore, local IgE production in non-allergic patients could explain the presence of symptoms in SPT negative patients (localised mucosal allergic disease in the absence of atopy – "entropy").¹¹⁰

Adverse reactions

In the last thirty years, the occurrence of systemic reactions with SPT for inhalant extracts has decreased dramatically.¹¹¹ Recent surveys indicate an overall risk inferior to 0.02% for anaphylactic reactions to SPT, whereas IDT are more likely to induce systemic reactions.¹¹¹ Most of the systemic reactions incited by SPT were related to fresh food (prick-prick tests with kiwi, fish, fresh pine nut and milk)¹¹²⁻¹¹⁴, latex (SPT with natural rubber latex and commercial extracts)^{115,116} and drugs (penicillin, amoxicillin).¹¹¹ In a 12-year survey of fatal reactions (1990-2001), one fatality was confirmed after SPT with multiple food allergens (90 food prick tests were applied at one time in a patient with moderately persistent asthma).¹¹⁷

A retrospective review of medical records concerning SPT with foods corroborates the low rate of generalised reactions, as previously stated, and points out that all reactions in infants (n = 6) occurred under 6 months of age and only with fresh food specimens.¹¹⁸

Special attention should be given to young children and pregnant women. Skin test duplication should be avoided in children with suspected food allergy (fresh food or commercial extracts), especially when suffering from extensive eczema.¹¹¹ As for pregnant women, although SPT is not contraindicated, it is prudent to postpone such procedures and/or propose sIgE assays instead.¹¹¹

Variability factors

Multiple factors have been found to influence SPT results. These variability factors include technical issues, biological determinants and other external factors such as previous medication or infections (Table I).

Skin reactivity is known to vary according to age: children, particularly under the age of 2 years, are less reactive than adults.¹¹⁹ The prevalence of positive skin test results increases until the 2nd decade, with a slow decline above the age of 60 years.¹²⁰ In children with manifest allergy, however, skin has similar reactivity from 1 year of age until puberty.⁴ Nevertheless, SPT tests can be used in infants as young as 1 month, with a high degree of reliability, usually with more erythema than wheal reaction.¹¹⁹

Test results also depend on anatomic location since skin reactivity differs from region to region. In decreasing order, the degrees of reactivity are as follows: mid and upper back > lower back > upper arm > elbow > forearm (ulnar > radial) > wrist.⁴⁷

Besides age and anatomic location, other biological and physiological factors may also influence skin test results,

Table I. False results in skin prick tests

	False negative results	False positive results
Biological factors	Sensitisation, sex, race, age and anatomic location	Dermographism
External factors	Drugs, UV radiation and other diseases	Cross-reactivity
Technical factors	Extract quality/concentration and incorrect technique	Trauma and non-blood-free procedure, extract quality (impure mixtures)
SPT diagnostic limitations	Non-allergic hypersensitivity and on-IgE mediated reactions	

such as histologic qualities of the skin (vascularity, number of histamine receptors, mast cells, and dermal thickness).²⁹ In one study, UV-B exposure was found to reduce skin reaction by as much as 48%.¹²¹ Concerning racial factors, dark-skinned patients seem to have larger wheal-and-flare reactions, but some authors found Caucasians to be more reactive than non-Caucasians.^{10,46}

Circadian rhythm has no influence on skin reactivity^{10,122} but some data show maximum wheal size during the night.⁴⁶ Different studies identified a relevant increase in wheal-and-flare reaction in patients with allergic asthma and rhinitis after pollen season.¹²³ On the contrary, the reduction in skin reactivity in sensitised subjects is a common finding after specific immunotherapy, either sublingual or subcutaneous.^{124,125}

Concurrent drugs, in particular antihistamines (AH), tricyclic antidepressants and topical corticosteroids may affect the validity of skin testing.¹⁰ Different pharmacodynamic

models have been used to evaluate the degree and duration of drug suppression on skin reactivity, making direct comparisons unreliable (Table II).

The histamine-induced wheal and flare model helps to identify the objective effectiveness of AH in humans, as well as their differences in the onset and duration of action. Several studies have employed this model to compare AH and assess their pharmacokinetic properties. When compared to other 2nd generation AH, such as desloratadine, levocetirizine appears to be more effective in inhibiting wheal and flare response.^{126,127} Ebastine, fexofenadine, cetirizine and mizolastine rank next and have similar skin effects. Superior efficacy of ebastine (20 mg) was found in comparison to cetirizine (10 mg) or loratadine (10 mg) on the overall skin wheal response after single and multiple doses,¹²⁷ with a longer-acting effect than fexofenadine as well.¹²⁸

The general principle concerning first- and second-generation AH is to stop medication 2 to 3 days before SPT, with the exception of cetirizine, hydroxyzine (5 days)¹²⁹, clemastine (5 days)¹³⁰, loratadine (7 days)¹³¹ and perhaps others not yet studied. For this reason, and as it seems easier for the patient to remember, we suggest a one-week drug-free interval before skin testing.

Many patients who require SPT cannot deal with pruritus without taking AH. In a recent work by Danarti et al¹³² topical AH can be used in such circumstances. Because of their short duration of action (< 180 minutes), these drugs can be used in patients who need antihistamines but are scheduled to undergo skin prick testing after a few hours, without influencing the patient's skin response.¹³²

Doxepin, a tricyclic antidepressant, and anti-H₂ drugs can also cause false-negative results for as long as 6 days¹³³ or 24h¹³⁴, respectively.

Systemic corticosteroids do not inhibit skin reactivity when used for short term therapy (i.e. 30 mg prednisone a day for 1 week).¹³⁵ When used for longer periods, conflicting results have been obtained, recommending a more critical analysis.¹⁰ Topical steroids should be discontinued 2 to 3 weeks before testing as prolonged use (over 3 weeks) can suppress wheal reaction in the application sites.¹³⁶

Bronchodilators, epinephrine and theophylline do not significantly suppress skin reactivity.¹³⁷ In the case of cysteinyl leukotrienes antagonists (e.g. montelukast and zafirlukast)¹³⁸ or EMLA cream¹³⁹, no significant effect on wheal-and-flare reaction has been described either. Concerning intranasal topical AH (e.g. azelastine) results are somehow contradictory and discontinuance is recommended for a 48h minimum period.^{10,140}

Table II. List of drugs with skin inhibitory effect

Drugs and skin reactivity		
Drug	Dose	Wheal inhibitory effect (days)
Anti-H ₁ 1 st generation		
Clemastine	1 mg 2×/d	5-10
Hydroxyzine	25 mg 4×/d	5-8
Promethazine	25 mg 4×/d	3-5
Anti-H ₁ 2 nd generation		
Fexofenadine	60 mg 2×/d	2
Loratadine	10 mg 1×/d	7
Cetirizine	10 mg 1×/d	3
Tricyclic antidepressants		
Desipramine	25 mg 1×/d	2
Doxepine	25 mg 1×/d	6
Cysteinyl leukotriene antagonists		
Montelukast	10 mg 1×/d	0
Zafirlukast	20 mg 1×/d	0
Local anesthetic		
EMLA cream	5 mg	0 (but suppresses erythema)
Anti-H ₂		
Ranitidine	150 mg 1 dose	< 1

Papule size depends as well on allergen concentration and number of allergens tested for which the patient is sensitised. Some authors have studied these variables and calculated, as an example, that the wheal diameter increases 1:5 times (area 2:5 times) if the allergen concentration increases 10 times.^{53,54} In polysensitised individuals, simultaneous prick testing with multiple allergens can induce additive histamine release from cutaneous mast cells. In vivo and in vitro studies suggest an additive effect of multiple proteins (allergens mixture) on histamine release from cutaneous mast cells, causing mean wheal diameters larger than obtained with single allergens.¹⁴¹

Future directions

Skin testing remains an essential diagnostic tool in modern allergy practice. Allergen extracts have experienced great progress in recent years but a long way remains ahead. Many allergens have yet to be characterized. The quality of extracts still needs further advances, with criterious allergen selection and biologic potency assessment. The capacity to differentiate between clinically irrelevant and relevant sensitisations constitutes an important motivation to future investigations. The definition and use of recombinant allergens promises to lead to an improvement in this area, eliminating diagnostic errors due to cross-reactivity phenomena.

References

- Larregina AT, Falo LD Jr. Changing paradigms in cutaneous immunology: adapting with dendritic cells. *J Invest Dermatol* 2005;124:1-12.
- Blackley CH. *Experimental Researches on the Causes and Nature of Catarrhus aestivus (Hay Fever or Hay-Asthma)*. London, England: Balliere Tindall & Cox; 1873.
- Feinberg SM. *Allergy in Practice*. 2nd ed. Chicago, IL: Year Book Medical Publishers; 1946.
- Dreborg S. Methods for skin testing. *Allergy* 1989;44:22-30.
- Lewis T, Grant RT. Vascular reactions of the skin to injury. *Heart* 1924;13:219-25.
- Pepys J. Skin testing. *Br J Hosp Med* 1975;14:412-6.
- Ishizaka K, Ishizaka T. Physicochemical properties of reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier reaginic activity. *J Immunol* 1966;97:75-85.
- Walzer M. Skin testing. In: Cooke RA. *Allergy in Theory and Practice*. Philadelphia, PA: WB Saunders; 1947. p. 502.
- Oppenheimer J, Nelson HS. Skin testing: a survey of allergists. *Ann Allergy Asthma Immunol* 2006;96:19-23.
- Bernstein IL, Li JT, Bernstein DI, Hamilton R, Spector SL, Tan R, et al. Allergy diagnostic testing: an updated practice parameter. *Ann Allergy* 2008;100:1-153.
- Fikrig E, Insel R, Knights A, Lolis E, Pawelec G, Vitetta E. Manipulation of the Immune Response. In: Eleanor L, Georgia B, eds. *Immunobiology, the Immune System in Health and Disease*. New York: Garland Science Publishing; 2005. p. 613-62.
- Petersen LJ, Mosbech H, Skov PS. Allergen-induced histamine release in intact human skin in vivo assessed by skin microdialysis technique: characterization of factors influencing histamine releasability. *J Allergy Clin Immunol* 1996;97:672-9.
- Almeida MM, Pires G, Prates S, Santa Marta C, Pinto PL. Testes cutâneos por *prick* – normalização e aplicações. *Rev Port Imunol* 1996;4:201-29.
- Hamilton RG, Adkinson NF Jr. Clinical laboratory assessment of IgE-dependent hypersensitivity. *J Allergy Clin Immunol* 2003;111:687-701.
- Barreto BA, Daher S, Naspitz CK, et al. Specific and non-specific nasal provocation tests in children with perennial allergic rhinitis. *Allergol Immunopathol* 2001; 29:255-63.
- Krouse JH, Sadrazodi K, Kerswill K. Sensitivity and specificity of prick and intradermal testing in predicting response to nasal provocation with timothy grass antigen. *Otolaryngol Head Neck Surg* 2004;131:215-9.
- Eigenmann PA, Sampson HA. Interpreting skin prick tests in the evaluation of food allergy in children. *Pediatr Allergy Immunol* 1998;9:186-91.
- Saarinen KM, Suomalainen H, Savilahti E. Diagnostic value of skin prick and patch tests and serum eosinophil cationic protein and cow's milk-specific IgE in infants with cow's milk allergy. *Clin Exp Allergy* 2001;31:423-9.
- Jacinto CM, Nelson RP, Bucholtz GA, Fernandez-Caldas E, Trudeau WL, Lockey RF. Nasal and bronchial provocation challenges with bayberry (*Myrica cerifera*) pollen extract. *J Allergy Clin Immunol* 1992;90:312-8.
- Burge HA. Fungus allergens. *Clin Rev Allergy* 1985;3:319-29.
- Zarei M, Remer CF, Kaplan MS, et al. Optimal skin prick wheal size for diagnosis of cat allergy. *Ann Allergy Asthma Immunol* 2004;92:604-10.
- Vandenplas O, Binard-Van Cangh F, Brumagne A, et al. Occupational asthma in symptomatic workers exposed to natural rubber latex: evaluation of diagnostic procedures. *J Allergy Clin Immunol* 2001;107:542-7.
- Park JW, Kim CW, Kim KS, et al. Role of skin prick test and serological measurement of specific IgE in the diagnosis of occupational asthma resulting from exposure to vinyl sulphone reactive dyes. *Occup Environ Med* 2001;58:411-6.
- Almqvist C, Li Q, Britton WJ, Kemp AS, Xuan W, Tovey ER, Marks GB. Early predictors for developing allergic disease and asthma: examining separate steps in the 'allergic march'. *Clin Exp Allergy* 2007;37:1296-302.
- Peat JK, Salome CM, Woolcock AJ. Longitudinal changes in atopy during a 4-year period: relation to bronchial hyperresponsiveness and respiratory symptoms in a population sample of Australian schoolchildren. *J Allergy Clin Immunol* 1990;85:65-74.
- Guilbert TW, Morgan WJ, Zeiger RS et al. Atopic characteristics of children with recurrent wheezing at high risk for the development of childhood asthma. *J Allergy Clin Immunol* 2004;114:1282-7.
- Williams H, Flohr C. How epidemiology has challenged 3 prevailing concepts about atopic dermatitis. *J Allergy Clin Immunol* 2006;118:209-13.
- Sampson HA. Update on food allergy. *J Allergy Clin Immunol* 2004;113:805-19.
- Rancé F, Juchet A, Brémont F, Dutau G. Correlations between skin prick tests using commercial extracts and fresh foods, specific IgE, and food challenges. *Allergy* 1997;52:1031-5.
- Rosen JP, Selcow JE, Mendelsen LM. Grodofsky Mt⁺, ??? Factor JM. Sampson HA. Skin testing with natural foods in patients suspected of having food allergies: is it a necessity? *J Allergy Clin Immunol* 1994;93:1068-70.
- Atkins FM, Steinberg SS, Metcalfe DD. Evaluation of immediate adverse reactions to foods in adult patients 1. Correlation of demographic, laboratory and prick skin test data with response to controlled oral food challenge. *J Allergy Clin Immunol* 1985;70:348-55.
- Sampson HA. Food Allergy. Part 2: diagnosis and management. *J Allergy Clin Immunol* 1999;103:981-99.
- Ortolani C, Ispano M, Pastorello EA, Ansaloni R, Magri GC. Comparison of results of skin prick tests (with fresh foods and commercial food extracts) and RAST in 100 patients with oral allergy syndrome. *J Allergy Clin Immunol* 1989;83:683-90.

34. Norgaard A, Skov PS, Bindslev-Jensen C. Egg and milk allergy in adults: comparison between fresh foods and commercial allergen extracts in skin prick test and histamine release from basophils. *Clin Exp Allergy* 1992;22:940-7.
35. Zeiss CR, Patterson R, Pruzansky JJ. Trimellitic anhydride-induced airway syndromes: clinical and immunologic studies. *J Allergy Clin Immunol* 1977;60:96-103.
36. Bourne MS, Flindt ML, Walker JM. Asthma due to industrial use of chloramine. *BMJ* 1979;2:10-2.
37. Munoz X, Crux MJ, Orriois R. Occupational asthma due to persulfate salts: diagnosis and follow-up. *Chest* 2003;123:2124-9.
38. Carr WW, Martin B, Howard RS, Cox L, Borish L. Comparison of test devices for skin prick testing. *J Allergy Clin Immunol* 2005;116:341-6.
39. Østerballe O, Weeke B. A new lancet for skin prick testing. *Allergy J* 1979;209-12.
40. Nelson HS, Lahr J, Buchmeier A, McCormick D. Evaluation of devices for skin prick testing. *J Allergy Clin Immunol* 1998;101:153-6.
41. Basomba A, Sastre A, Pelaez A, Romar A, Campos A, Garcia-Villalmanzo A. Standardization of the prick test. A comparative study of three methods. *Allergy* 1985;40:395-9.
42. Holgersson M, Stahlenheim G, Dreborg S. The precision of skin prick test with Phazet TM, the Østerballe needle and the bifurcated needle. *Allergy* 1985;40:64-5.
43. Demoly P, Piette V, Bousquet J. In vivo methods for study of allergy: skin tests, techniques and interpretation. Adkinson NF Jr, Yunginger JW, Busse IW, Bochner BS, Holgate ST, Simons, FE eds. 6th edn. *Allergy, principles and practice*. New York: Mosby Co, 2004, 631-41.
44. Voorhorst R. Perfection of skin testing technique. A review. *Allergy* 1980;35:247-50.
45. Terho EO, Husman K, Kivekas J, Rihimäki H. Histamine control affects the weal produced by the adjacent diluent control in skin prick tests. *Allergy* 1989;44:30-2.
46. Almeida MM, Gaspar A, Romeira A, Sampaio G, Teixeira C, Câmara R, et al. Reactividade cutânea inespecífica em estudos populacionais. *Rev Port Imunoalergol* 2001;8:199-204.
47. Nelson HS, Knoetzer J, Bucher B. Effect of distance between sites and region of the body on results of skin prick tests. *Journal Allergy Clin Immunol* 1996;97:596-601.
48. Aas K, Backman A, Belin L, Weeke B. Standardization of allergen extracts with appropriate methods. The combined use of skin prick testing and radioallergosorbent test. *Allergy* 1978;33:130-7.
49. Mailing HJ. Skin prick testing and the use of histamine references. *Allergy* 1984;35:596-601.
50. Scandinavian Society of Allergology. Standardization of diagnostic work in allergy. *Acta Allergol* 1974;29:239-40.
51. Dreborg S, Foucard T. Allergy to apple, carrot and potato in children with birch pollen allergy. *Allergy* 1983;38:167-71.
52. Paschke A, Besler M. Stability of bovine allergens during food processing. *Ann Allergy Asthma Immunol* 2002;89:16-20.
53. Dreborg S, Holgersson M, Nilsson G, Zetterstrom MO. Dose response relationship of allergen, histamine, and histamine releasers in skin prick test and precision of the skin prick test method. *Allergy* 1987;42:117-25.
54. Dreborg S, Belin L, Eriksson NE, et al. Results of biological standardization with standardized allergen preparations. *Allergy* 1987;42:109-16.
55. Dreborg S, Nilsson G, Zetterstrom MO. The precision of intracutaneous skin test with timothy pollen allergen preparation using two different techniques. *Ann Allergy* 1987;58:33-5.
56. Vohlonen I, Terho EO, Koivikko A, Vanto T, Holmen A, Heinonen OP. Reproducibility of the skin prick test. *Allergy* 1989;44:525-31.
57. Dreborg S. Skin tests used in type 1 allergy testing. Position paper prepared by the subcommittee on skin tests of the European Academy of Allergology and Clinical Immunology. *Allergy* 1989;44:1-59.
58. Oppenheimer J, Nelson HS. Skin testing. *Ann Allergy Asthma Immunol* 2006;96:6-12.
59. Dreborg S. Histamine reactivity of the skin. *Allergy* 2001;56:359-64.
60. Abramoff MD, Magelhaes PJ, Ram SJ. Image processing with ImageJ. *Biophoton Int.* 2004;11:36-42.
61. Lamminen H, Voipio V. Computer-aided skin prick test. *Exp Dermatol* 2008;17:975-6.
62. Serup J. Diameter, thickness, area and volume of skin prick histamine weals. Measurement of skin thickness by 15MHz-A-mode ultrasound. *Allergy* 1984;35:359-64.
63. Serup J, Staberg B. Quantification of weal reactions with laser doppler flowmetry. Comparative blood flow measurements of the oedematous centre and the peri-lesional flare of skin prick histamine weals. *Allergy* 1985;40:233-7.
64. Dreborg S, Frew A. Position Paper Allergen standardization and skin tests. *Allergy* 1993;48:48-82.
65. Koller DY, Pirker C, Jarisch R, et al. Influence of the histamine control on skin reactivity in skin testing. *Allergy* 1992;47:58-9.
66. Krouse JH, Mabry RL. Skin testing for inhalant allergy 2003: Current strategies. *Skin testing for inhalant allergy 2003: current strategies*. *Otolaryngol Head Neck Surg* 2003;129:33-49.
67. Adinoff AD, Rosloniec DM, McCall LL, et al. A comparison of six epicutaneous devices in the performance of immediate hypersensitivity skin testing. *J Allergy Clin Immunol* 1989;84:168-74.
68. Stuckey MS, Witt CS, Schmitt LH, Warlow R, Lattimore M, Dawkins RL. Histamine sensitivity influences reactivity to allergens. *J Allergy Clin Immunol* 1985;75:373-6.
69. Berkowitz RB, Tinkelman DG, Lutz C, et al. Evaluation of the Multi-Test device for immediate hypersensitivity skin testing. *J Allergy Clin Immunol* 1992;90:979-85.
70. McCann WA, Ownby DR. The reproducibility of the allergy skin test scoring and interpretation by board-certified/board-eligible allergists. *Ann Allergy Asthma Immunol* 2002;89:368-71.
71. Celik-Bilgili S, Mehl A, Verstege A et al. The predictive value of specific immunoglobulin E levels in serum for the outcome of oral food challenges. *Clin Exp Allergy* 2005;35:268-73.
72. Sampson HA. Utility of food-specific IgE concentrations in predicting symptomatic food allergy. *J Allergy Clin Immunol* 2001;107:891-6.
73. García-Ara C, Boyano-Martínez T, Díaz-Pena JM, Martín-Munoz F, Reche-Frutos M, Martín-Esteban M. Specific IgE levels in the diagnosis of immediate hypersensitivity to cow's milk protein in the infant. *J Allergy Clin Immunol* 2001;107:185-90.
74. Sporik R, Hill DJ, Hosking CS. Specificity of allergen skin testing in predicting positive open food challenges to milk, egg and peanut in children. *Clin Exp Allergy* 2000;30:1540-6.
75. Verstege A, Mehl A, Rolinck-Werninghaus C, Staden U, Nocont M, Beyer K, et al. The predictive value of the skin prick test weal size for the outcome of oral food challenges. *Clin Exp Allergy* 2005;35:1220-6.
76. Roberts G, Lack G. Food allergy — getting more out of your skin prick tests. *Clin Exp Allergy* 2000;30:1495-8.
77. Perry TT, Matsui EC, Kay Conover-Walker M, et al. The relationship of allergen-specific IgE levels and oral food challenge outcome. *J Allergy Clin Immunol* 2004;114:144-9.
78. Sicherer SH, Morrow EH, Sampson HA. Dose-response in double-blind, placebo-controlled oral food challenges in children with atopic dermatitis. *J Allergy Clin Immunol* 2000;105:582-6.
79. Monti G, Muratore MC, Peltran A, et al. High incidence of adverse reactions to egg challenge on first known exposure in young atopic dermatitis children: predictive value of skin prick test and radioallergosorbent test to egg proteins. *Clin Exp Allergy* 2002;32:1515-9.

80. Haahtela T, Heiskala M, Suoniemi I. Allergic disorders and immediate skin test reactivity in Finnish adolescents. *Allergy* 1980;35:433-41.
81. Backer V, Ulrik CS, Hansen KK, Laursen EM, Dirksen A, Bach-Mortensen N. Atopy and bronchial responsiveness in random population sample of 527 children and adolescents. *Ann Allergy* 1992;69:116-22.
82. Bodtger U, Poulsen LK, Malling HJ. Asymptomatic skin sensitization to birch predicts later development of birch pollen allergy in adults: a 3-year follow-up study. *J Allergy Clin Immunol* 2003;111:149-54.
83. Perkin MR, Strachan DP, Williams HC, Kennedy CT, Golding J. Natural history of atopic dermatitis and its relationship to serum total immunoglobulin E in a population-based birth cohort study. *Pediatr Allergy Immunol* 2004;15:221-9.
84. Burr ML, Merrett TG, Dunstan FD, Maguire MJ. The development of allergy in high-risk children. *Clin Exp Allergy* 1997;27:1247-53.
85. Lilja G, Oman H, Johansson SG. Development of atopic disease during childhood and its prediction by Phadiatop Paediatric. *Clin Exp Allergy* 1996;26:1073-9.
86. Zeiger RS, Heller S. The development and prediction of atopy in high-risk children: follow-up at age seven years in a prospective randomized study of combined maternal and infant food allergen avoidance. *J Allergy Clin Immunol* 1995;95:1179-90.
87. A. Lowe AJ, Abramson MJ, Hosking CS, Carlin JB, Bennett CM, Dharmage SC, et al. The temporal sequence of allergic sensitization and onset of infantile eczema. *Clin Exp Allergy* 2007;37:536-42.
88. Focke M, Marth K, Flicker S, Valenta R. Heterogeneity of commercial timothy grass pollen extracts. *Clin Exp Allergy* 2008;38:1400-8.
89. Larenas-Linnemann D, Cox LS; Immunotherapy and Allergy Diagnostics Committee of the American Academy of Allergy, Asthma and Immunology. European allergen extract units and potency: review of available information. *Ann Allergy Asthma Immunol* 2008;100:137-45.
90. Larsen JN, Dreborg S. Standardization of allergen extracts. *Methods Mol Med* 2008;138:133-45.
91. Dreborg S, Einarsson R. The major allergen content of allergenic preparations reflect their biological activity. *Allergy* 1992;47:418-23.
92. Platts-Mills TA, Chapman MD. Allergen standardization. *J Allergy Clin Immunol* 1991;87:621-5.
93. Eichler I, Götz M, Jarisch R, Eichler HG, Moss R. Reproducibility of skin prick testing with allergen extracts from different manufacturers. *Allergy* 1988;43:458-63.
94. Nelson HS. Effect of preservatives and conditions of storage on the potency of allergy extracts. *J Allergy Clin Immunol* 1981;67:64-7.
95. Niemeijer NR, Kauffman HF, van Hove W, et al. Effect of dilution, temperature, and preservatives on the long-term stability of standardized inhalant allergen extracts. *Ann Allergy Asthma Immunol* 1996;76:535-40.
96. Schmid-Grendelmeier P, Crameri R. Recombinant allergens for skin testing. *Int Arch Allergy Immunol* 2001;125:96-111.
97. www.isac.cnr.it/aerobio/ai
98. <http://www.rpaerobiologia.com>
99. Swick H, Papp W, Jager S, et al. Pollen sensitization and allergy in children depend on the pollen load. *Allergy* 1991;14:362-6.
100. Ortolani C, Ispano M, Pastorello EA, Ansaloni R, Magri GC. Comparison of results of skin prick tests (with fresh foods and commercial food extracts) and RAST in 100 patients with oral allergy syndrome. *J Allergy Clin Immunol* 1989;83:683-90.
101. Bolhaar ST, van de Weg WE, van Ree R, et al. In vivo assessment with prick-to-prick testing and double-blind, placebo-controlled food challenge of allergenicity of apple cultivars. *J Allergy Clin Immunol* 2005;116:1080-6.
102. Ziegert M, Beyer K, Wahn, Niggemann B. Effect of freezing foods for the outcome of skin prick tests. *Allergy* 2007;62:818-9.
103. Aas K. Some variables in skin prick testing. Standardization of clinical (biological) methods. *Allergy* 1980;36:250-2.
104. Lowe AJ, Hosking CS, Bennett CM, Carlin JB, Abramson MJ, Hill DJ, Dharmage SC. Skin prick test can identify eczematous infants at risk of asthma and allergic rhinitis. *Clin Exp Allergy* 2007;37:1624-31.
105. Van der Veen MJ, Mulder M, Witterman AM, van Ree R, Aalberse RC, Jansen HM, et al. False-positive skin prick test responses to commercially available dog dander extracts caused by contamination with house dust mite (*Dermatophagoides pteronyssinus*) allergens. *J Allergy Clin Immunol* 1996;98:1028-34.
106. Ferreira F, Hawranek T, Gruber P, Wopfner N, Mari A. Allergic cross-reactivity: from gene to the clinic. *Allergy* 2004;59:243-67.
107. Weber RW. Patterns of pollen cross allergenicity. *J Allergy Clin Immunol* 2003;112:229-39.
108. Sicherer SH. Clinical implications of cross-reactive food allergens. *J Allergy Clin Immunol* 2001;108:881-90.
109. Blanco C. Repercusión clínica de la reactividad cruzada. *Alergol Immunopathol* 2001;9:99-102.
110. Powe DG, Jones NS. Local mucosal immunoglobulin E production: does allergy exist in non-allergic rhinitis? *Clin Exp Allergy* 2006;36:1367-72.
111. Liccardi G, D'Amato G, Canonica GW, Salzillo A, Piccolo A, Passalacqua G. Systemic reactions from skin testing: literature review. *J Investig Allergol Clin Immunol* 2006;16:75-8.
112. Novembre E, Bernardini R, Bertini G, Massai G, Vierucci A. Skin-prick-test-induced anaphylaxis. *Allergy* 1995;50:511-3.
113. Van de Scheur MR, Bruynzeel DP. Acute anaphylaxis after pine nut skin testing. *Ann Allergy Asthma Immunol* 2004;92:93.
114. Dreborg S. The risk of general reactions to skin prick testing. *Allergy* 1996;51:60-1.
115. Nicolaou N, Johnston GA. Anaphylaxis following prick testing with natural rubber latex. *Contact Dermatitis* 2002;47:251-52.
116. Kelly KJ, Kurup VP, Zacharisen MC, Resnick A, Fink JN. Skin and serologic testing in the diagnosis of latex allergy. *J Allergy Clin Immunol* 1993;91:1140-45.
117. Bernstein DI, Wanner M, Borish L, et al; Immunotherapy Committee, American Academy of Allergy, Asthma and Immunology. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. *J Allergy Clin Immunol* 2004;113:1129-36.
118. Devenney I, Magnusson KF. Skin prick tests may give generalized allergic reactions in infants. *Ann Allergy Asthma Immunol* 2000;85:457-60.
119. Ménardo JL, Bousquet J, Rodière M, Astruc J, Michel FB. Skin test reactivity in infancy. *J Allergy Clin Immunol* 1985;75:646-51.
120. Skassa-Brociek W, Manderscheid JC, Michel FB, Bousquet J. Skin test reactivity to histamine from infancy to old age. *J Allergy Clin Immunol* 1987;80:711-6.
121. Vocks E, Stander K, Rakoski J, et al. Suppression of immediate-type hypersensitivity elicitation in the skin prick test by ultraviolet B irradiation. *Photodermatol Photoimmunol Photomed* 1999;15:236-40.
122. Vichyanond P, Nelson HS. Circadian variation of skin reactivity and allergy skin tests. *J Allergy Clin Immunol* 1989;83:1101-6.
123. Oppenheimer J, Nelson HS. Seasonal variation in immediate skin test reactions. *Ann Allergy* 1993;71:227-9.
124. Pichler CE, Helbling A, Pichler WJ. Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-spe-

- cific parameters and of nonspecific bronchial hyperreactivity. *Allergy*. 2001;56:301-6.
125. Bordignon V, Parmiani S. Variation of the skin end-point in patients treated with sublingual specific immunotherapy. *J Investig Allergol Clin Immunol*. 2003;13:170-6.
 126. Grant JA, Riethuisen JM, Moolaert B, DeVos C. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. *Ann Allergy Asthma Immunol* 2002;88:190-7.
 127. Gispert J, Antonijoan R, Barbanøj M, Gich I, Garcia E, Esbrí R, Luria X. Efficacy of ebastine, cetirizine and loratadine in histamine cutaneous challenges. *Ann Allergy Asthma Immunol* 2002;89:259-64.
 128. Barbanøj MJ, Antonijoan RM, García-Gea C, Morte A, Gich I, Gispert J, Garcia E, Esbrí R, Luria X. A study comparing the inhibitory effects of single and repeated oral doses of ebastine and fexofenadine against histamine-induced skin reactivity. *Int Arch Allergy Immunol*. 2003;132:263-7.
 129. Long WF, Taylor RJ, Wagner CJ, Leavengood DC, Nelson HS. Skin test suppression by antihistamines and the development of subsensitivity. *J Allergy Clin Immunol* 1985;76:113-7.
 130. Cook TJ, MacQueen DM, Wittig HJ, Thornby JI, Lantos RL, Virtue CM. Degree and duration of skin test suppression and side effects with antihistamines: a double blind controlled study with five antihistamines. *J Allergy Clin Immunol* 1973; 51:71-7.
 131. Imind M, Dirksen A, Nielsen NH, Svendsen UG. Duration of the inhibitory activity on histamine-induced skin wheals of sedative and non-sedative antihistamines. *Allergy* 1988;43: 593-6.
 132. Danarti R, Waskito F, Indrastuti N. Onset and duration of action of topical antihistamine: a study of histamine skin test response. *Int J Dermatol* 2008;47:861-3.
 133. Rao KS, Menon PK, Hillman BC, et al. Duration of the suppressive effect of tricyclic antidepressants on histamine-induced wheal-and-flare reactions in human skin. *J Allergy Clin Immunol* 1988;82:752-7.
 134. Miller J, Nelson HS. Suppression of immediate skin tests by ranitidine. *J Allergy Clin Immunol* 1989;84:895-9.
 135. Des Roches A, Paradis L, Bougeard YH, et al. Long-term oral corticosteroid therapy does not alter the results of immediate-type allergy skin prick tests. *J Allergy Clin Immunol* 1996; 98:522-7.
 136. Pipkorn U, Hammarlund A, Enerbach L. Prolonged treatment with topical glucocorticoids results in an inhibition of the allergen-induced weal-and-flare response and a reduction in skin mast cell numbers and histamine content. *Clin Exp Allergy*. 1989;19:19-25.
 137. Pipkorn U. Pharmacological influence of anti-allergic medication on in vivo allergen testing. *Allergy* 1988;43:81-86.
 138. Simons FE, Johnston L, Gu X, Simons KJ. Suppression of the early and late cutaneous allergic responses using fexofenadine and montelukast. *Ann Allergy Asthma Immunol* 2001;86:44-50.
 139. Sicherer SH, Eggleston PA. EMLA cream for pain reduction in diagnostic allergy skin testing: effects on wheal and flare responses. *Ann Allergy Asthma Immunol* 1997;78:64-8.
 140. Agarwal MK, Vijayan VK, Vermani M. Effect of azelastine nasal spray on histamine- and allergen-induced skin wheal response in patients with allergic rhinitis. *J Asthma* 2008;45:548-51.
 141. Liccardi G, Passalacqua G, Falagiani P, Russo M, D'Amato G. The effect of multiple allergens on histamine release in vivo assessed by skin prick test. *Allergy*. 2008;63:1559-60.